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Abstract
Introduction
The Disease Management Association of America identifies 
diabetes as one of the chronic conditions with the great-
est  potential  for  management.  TRICARE  Management 
Activity, which administers health care benefits for US 
military service personnel, retirees, and their dependents, 
created a disease management program for beneficiaries 
with diabetes. The objective of this study was to determine 
whether  participation  intensity  and  prior  indication  of 
uncontrolled diabetes were associated with health care use 
and costs for participants enrolled in TRICARE’s diabetes 
management program.
Methods
This  ongoing,  opt-out  study  used  a  quasi-experimental 
approach to assess program impact for beneficiaries (n = 
37,370) aged 18 to 64 living in the United States. Inclusion 
criteria were any diabetes-related emergency department 
visits or hospitalizations, more than 10 diabetes-related 
ambulatory visits, or more than twenty 30-day prescrip-
tions for diabetes drugs in the previous year. Beginning in 
June 2007, all participants received educational mailings. 
Participants who agreed to receive a baseline telephone 
assessment and telephone counseling once per month in 
addition to educational mailings were considered active, 
and  those  who  did  not  complete  at  least  the  baseline 
telephone  assessment  were  considered  passive.  We  cat-
egorized the diabetes status of each participant as “uncon-
trolled”  or  “controlled”  on  the  basis  of  medical  claims 
containing diagnosis codes for uncontrolled diabetes in the 
year preceding program eligibility. We compared observed 
outcomes to outcomes predicted in the absence of diabetes 
management. Prediction equations were based on regres-
sion  analysis  of  medical  claims  for  a  historical  control 
group (n = 23,818) that in October 2004 met the eligibility 
criteria for TRICARE’s program implemented June 2007. 
We  conducted  regression  analysis  comparing  historical 
control group patient outcomes after October 2004 with 
these baseline characteristics.
Results
Per-person total annual medical savings for program par-
ticipants, calculated as the difference between observed 
and  predicted  outcomes,  averaged  $783.  Active  partici-
pants had larger reductions in inpatient days and emer-
gency department visits, larger increases in ambulatory 
visits, and larger increases in receiving retinal examina-
tions, hemoglobin A1c tests, and urine microalbumin tests 
compared  with  passive  participants.  Participants  with 
prior indication of uncontrolled diabetes had higher per-
person total annual medical savings, larger reduction in 
inpatient days, and larger increases in ambulatory visits 
than did participants with controlled diabetes.
Conclusion
Greater intensity of participation in TRICARE’s diabetes 
management program was associated with lower medical 
costs and improved receipt of recommended testing. That 
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patients  who  were  categorized  as  having  uncontrolled 
diabetes realized greater program benefits suggests dia-
betes management programs should consider indication of 
uncontrolled diabetes in their program candidate identifi-
cation criteria.
Introduction
Disease management programs educate patients and teach 
them self-management skills that lead to more healthful 
lifestyle choices and appropriate use of health care services. 
These improvements can produce better health outcomes 
and  reduced  medical  costs.  The  Disease  Management 
Association of America describes type 2 diabetes as one of 
the chronic diseases best suited for disease management; 
most studies have found improved patient outcomes after 
participation in diabetes management programs (1-3).
TRICARE Management Activity, the health care benefits 
administrator for US military service personnel, covers 9.4 
million beneficiaries (active-duty service members, family 
members, and retirees and their family members); approx-
imately 225,000 beneficiaries who are aged 18 to 64 years 
and ineligible for Medicare have been diagnosed with dia-
betes (4). In June 2007, TRICARE Management Activity 
contracted with its 3 regional managed care support con-
tractors  to  implement  a  diabetes  management  program 
for patients whose medical records indicated high use of 
health care services. To improve patient selection criteria 
for  program  eligibility,  inform  program  structure  and 
content,  and  evaluate  diabetes  management  programs, 
we  assessed  TRICARE’s  disease  management  program 
to determine whether and how patient outcomes differed 
by need for diabetes management (defined by indication 
of uncontrolled diabetes preceding program participation) 
and  by  intensity  of  program  participation  (defined  by 
active or passive participation).
Methods
Overview
Patients were eligible to participate in this voluntary, opt-
out program if during the previous 12-month period they 
had  any  diabetes-related  emergency  department  (ED) 
visits or hospitalizations, more than 10 diabetes-related 
ambulatory visits, or more than twenty 30-day prescrip-
tions for diabetes drugs.
From June 2007 through September 2008, 37,370 patients 
were automatically selected for enrollment in this program; 
11% opted out. Among program participants, approximate-
ly 25% chose to receive personalized telephone counseling. 
Services included a baseline assessment by telephone with 
a care manager (lasting 40-50 min); monthly telephone 
calls to educate patients and assess progress toward goals; 
educational materials (eg, pamphlets, videos, cookbooks); 
and newsletters and online materials. These patients were 
categorized as “active” participants. The remaining 75% 
of patients, categorized as “passive” participants, received 
newsletters but chose not to receive personalized counsel-
ing. All patients could contact care managers by telephone 
if they had questions about their diabetes, and they could 
access  Internet-based  educational  resources.  Additional 
information about TRICARE’s disease management pro-
gram is available elsewhere (5,6).
The voluntary, opt-out nature of this program, which based 
eligibility on high use of health care services, introduced 3 
phenomena that we considered in the evaluation design. 
First, selection bias occurs when highly motivated patients 
are more likely to participate, participate at higher inten-
sity, or more actively manage their disease. Second, regres-
sion to the mean occurs when program eligibility is deter-
mined by high use of health care services. That is, patient 
medical costs and health care use tend to decline in the 
period following program eligibility (even in the absence 
of a disease management program) when participants are 
identified on the basis of their high health care use. Third, 
the opt-out design does not allow for a concurrent natural 
comparison group to quantify program effect.
We identified a historical control group (HCG) and used 
this group’s information to develop equations predicting 
outcomes for patients in the absence of a diabetes manage-
ment program. To estimate program effect, we calculated 
the mean difference between patients’ observed and pre-
dicted outcomes.
To create the analytical database, we used a unique patient 
identifier that linked medical and pharmacy claims from 
the  Defense  Health  Information  Management  System 
Clinical  Data  Repository,  patient  characteristics  from 
the  Defense  Enrollment  Eligibility  Reporting  System, 
and disease management services received as indicated 
in  the  patient  tracking  information  systems  of  the  3 
disease  management  service  providers.  An  institutional 
review board (Independent Review Consulting, Inc, Corte 
Madera, California) approved the study protocols.VOLUME 8: NO. 3
MAY 2011
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Outcome metrics
On the basis of a literature review and data availability, 
we chose indicators considered best practices for evaluat-
ing program performance (7-9). Indicators of health care 
use  were  number  of  ED  visits,  hospital  inpatient  days, 
ambulatory visits, and number of prescriptions. We used 
the medical component of the Consumer Price Index to 
calculate TRICARE’s medical costs in 2008 dollars (10). 
Because most diabetes-attributed costs stem from its com-
plications and higher use of general medical services, we 
report both 1) diabetes-related costs and health care use 
and 2) total costs and health care use (excluding claims for 
injury, pregnancy, congenital abnormalities, and cancer) 
(11). Clinical indicators were the percentage of patients 
who annually received at least 1 hemoglobin A1c (HbA1c) 
test, dilated retinal examination, or urinary microalbumin 
test. Laboratory test results were unavailable.
Evaluation sample
From the 37,370 patients who were eligible for the pro-
gram,  we  excluded  1)  3,021  patients  with  fewer  than 
6  months’  program  enrollment  (for  insufficient  time  to 
complete the program), 2) 449 patients not continuously 
eligible for TRICARE during the evaluation period, 3) 218 
patients who became eligible for Medicare (for whom com-
plete medical records were unavailable), 4) 154 patients 
who  died  or  had  HIV/AIDS  or  end-stage  renal  disease 
(ESRD), and 5) 3,924 opt-out patients. The final sample 
contained  29,604  patients;  the  median  program  tenure 
was 15 months (Figure).
After  TRICARE  Management  Activity  identified  candi-
dates for the program, the disease management provider 
for each region contacted patients by letter and by tele-
phone. Patients could choose to receive personalized coun-
seling by telephone and mailing, to receive only the news-
letters and other mailings, or to have no further contact 
with the program (ie, opt out). The disease management 
providers did not record patients’ reasons for opting out. 
However, care managers said that opt-out patients’ typical 
reasons for choosing not to participate is that they would 
be unable to complete the program because of impending 
Figure. Evaluation model for the TRICARE diabetes disease management program, United States, 2007-2008. Abbreviations: ESRD, end-stage renal disease; 
HbA1c, hemoglobin A1c. VOLUME 8: NO. 3
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military  transfers  and  enlistment  terminations,  did  not 
have diabetes, or previously participated in other diabetes 
management  programs  and  did  not  believe  they  would 
benefit from participating in this program. Patients who 
opted out had similar demographic characteristics to those 
of participants but had slightly higher medical costs in the 
year preceding program eligibility.
The  patient-level  analytic  file  linked  medical  claims  to 
program participation records. For each patient, we sum-
marized health care use during 2 periods. The identifi-
cation  period  was  1  year  preceding  the  eligibility  date; 
the postidentification period varied from 7 months to 15 
months after the eligibility date. The outcome variables 
for each patient, standardized to a 12-month period, take 
into account a patient’s program tenure. Although medi-
cal claims for participants were available through March 
2009, to control for the time lag in claims processing and 
adjudication and to ensure we had complete claims data 
for participants, we allowed a minimum of 6 months from 
date  of  service  to  the  final  record  extraction  date  and 
ended the observation period at September 30, 2008.
We categorized patients as having uncontrolled diabetes if 
they had at least 1 episode of care with the  diagnosis code 
for uncontrolled diabetes (International Classification of 
Diseases, Ninth Revision, 250.02, 250.03) during the year 
preceding program eligibility. Although lack of a medical 
claim with a diagnosis of uncontrolled diabetes does not 
necessarily mean a patient’s glucose level was controlled, 
for discussion purposes we refer to these patients as hav-
ing “controlled” diabetes.
Historical control group
The  HCG  contained  23,818  patients  who  in  October 
2004  met  the  criteria  used  later  to  determine  eligibil-
ity for the program established in June 2007 (Figure). 
After excluding patients who died or had HIV/AIDS or 
ESRD,  the  HCG  analytic  sample  consisted  of  23,778 
patients. We used multivariable regression to assess the 
difference  between  patient  health  care  use  and  costs, 
by patient characteristics, postidentification (November 
2004  through  October  2005)  and  from  the  eligibility 
determination period (November 2003 through October 
2004).
We used Poisson regressions to analyze count variables 
such as inpatient days and ED visits, generalized linear 
models with gamma distribution to analyze health care 
costs,  and  logistic  regressions  to  analyze  dichotomous 
clinical variables such as having an HbA1c test during the 
year. Covariates included patient age group (18-34 y, 35-
54 y, 55-64 y) and sex; TRICARE region; military service 
branch; number of ED visits, inpatient days, ambulatory 
visits, and 30-day prescriptions; indication of uncontrolled 
diabetes;  Charlson  comorbidity  index  score  (12,13);  and 
medical  costs.  Regressions  to  estimate  diabetes-specific 
health  care  use  and  costs  incorporate  diabetes-specific 
health care use and cost covariates. We estimated sepa-
rate regressions for 1) patients covered under the man-
aged care plan and 2) patients in the preferred provider 
organization (PPO) plans.
Regression results, available from the authors on request, 
are  consistent  with  expectations.  For  example,  sicker 
patients  (ie,  those  with  a  higher  Charlson  comorbid-
ity  score)  in  the  November  2003  through  October  2004 
period had higher average health care use and costs in   
the  November  2004  through  October  2005  period.  The 
goodness-of-fit  measures  for  the  regressions  —  based 
on root mean square error for continuous outcomes and 
receiver operating curve for dichotomous outcomes — sug-
gest that the regressions are robust. We used the regres-
sion coefficients based on these HCG analyses to predict 
program participants’ annual health care use and costs.
Results
Sample characteristics
Of the 29,604 participants in the analytic sample, 12,776 
(43%) had indications of uncontrolled diabetes in the year 
preceding  program  start  (Table  1).  The  rates  of  active 
participation were similar for patients with indications of 
uncontrolled (26%) and controlled (25%) diabetes. A higher 
proportion of active participants than passive participants 
were in the managed care plan and had higher preprogram 
rates of receiving an HbA1c test, retinal examination, and 
microalbumin urine test. They also had a higher Charlson 
comorbidity score and higher preprogram health care use 
and medical costs.
The HCG was similar to the program participant group 
in demographic characteristics, medical costs, and health 
care use. However, patients in the HCG had lower rates of 
receiving appropriate tests, particularly HbA1c and micro-
albumin urine tests.VOLUME 8: NO. 3
MAY 2011
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Health care use and costs
Because  high  health  care  use  determined  program  eli-
gibility, patient health care use and cost outcomes were 
higher in the year preceding program eligibility than in 
the  year  following  eligibility  (as  extreme  scores  moved 
toward being less extreme). For the HCG, diabetes-related 
costs dropped by 28% and total costs dropped by 17% from 
the  preidentification  to  postidentification  period  (Table 
2). However, the decline was even larger for the program 
participants, who experienced 35% and 20% postprogram 
declines in annual diabetes-related and total costs, respec-
tively, compared with the year preceding program eligibil-
ity. Before adjusting for case mix, these estimates suggest 
that program participants generated $353 per year less in 
diabetes-related costs and $408 per year less in total costs 
than did the HCG group. The decline in diabetes-related 
costs  was  largest  for  patients  with  prior  indications  of 
uncontrolled diabetes, and the decline in total costs was 
largest for patients with no prior indication of uncontrolled 
diabetes.
Observed versus predicted outcomes
Program participants with prior indication of uncontrolled 
diabetes  had  higher  observed  diabetes-related  costs  per 
year (Table 3) and higher total costs per year (Table 4) 
than did patients with controlled diabetes. However, this 
outcome  was  expected,  based  on  prediction  equations 
generated  from  the  HCG  group,  because  patients  with 
uncontrolled  diabetes  had  higher  Charlson  comorbidity 
scores than did patients with no indication of uncontrolled 
diabetes in the year preceding eligibility.
The difference in observed and predicted outcomes (which 
controls  for  differences  in  case  mix  between  subsets  of 
program participants) suggests an average annual reduc-
tion in diabetes-related costs of $249 per person overall 
(Table 3). The reduction was largest among patients with 
a  previous  indication  of  uncontrolled  diabetes,  whether 
active ($388) or passive ($392), driven primarily by larger-
than-average reductions in use of inpatient services; the 
smallest decline in average annual diabetes-related costs 
was for active participants with controlled diabetes ($67) 
(data not shown). Costs associated with the rise in diabe-
tes-related ambulatory visits and receipt of tests partially 
offset medical savings associated with the modest decline 
in  use  of  hospital  services.  Program  participation  was 
associated with receiving an annual HbA1c test, retinal 
examination, and microalbumin urine test compared with 
the year preceding enrollment; active participants experi-
enced the greatest improvement.
The average per-person reduction in total costs was $783 
per year (Table 4). The reduction was largest for active 
participants  with  prior  indications  of  uncontrolled  dia-
betes ($1,007) and smallest for passive participants with 
controlled  diabetes  ($577)  (data  not  shown).  Compared 
with passive participants, active participants experienced 
larger declines in inpatient days and ED visits and larger 
increases in ambulatory visits. For passive participants, 
medical savings appear to be primarily realized through 
reduced use of prescription drugs.
Discussion
This  study  suggests  that  TRICARE’s  diabetes  man-
agement  program  is  associated  with  modest  annual   
reductions in medical costs and improved receipt of recom-
mended screening. Improvements were largest for active 
participants with prior indication of uncontrolled diabetes 
and smallest for patients with no prior indication of uncon-
trolled diabetes (whether active or passive participants). 
Active participants had greater improvements than pas-
sive participants in the proportion receiving appropriate 
screening.  Increased  costs  for  ambulatory  care  offset  a 
portion  of  medical  savings  from  reduced  inpatient  days 
and ED visits.
Our estimates of average annual medical savings among 
all program participants ($249 for diabetes-related costs 
and $783 for total costs) are within the range of estimates 
from  other  diabetes  management  programs.  Published 
estimates for other programs, which may differ from this 
program in terms of population served and intensity of 
services, suggest an average annual per-patient savings 
of $626 in diabetes-related costs (with estimates ranging 
from a $2,787 loss to a $4,329 gain) (2,14-16). This average 
comes from randomized clinical trials, quasi-experimental, 
and pre-post studies (although the sample sizes in these 
studies are much smaller than for our study). Studies that 
used a quasi-experimental design similar to our use of the 
HCG estimated average per-patient savings to be approxi-
mately $1,292 per year (2).
A major contribution of our study is that patients with 
prior indications of uncontrolled diabetes appear to expe-
rience  greater  program  benefits  than  do  patients  with 
no indication of uncontrolled diabetes in the 12 months VOLUME 8: NO. 3
MAY 2011
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preceding program eligibility. Patients with uncontrolled 
diabetes  who  want  to  improve  their  self-management 
skills (as indicated by active program participation) likely 
have the most to gain from an education-based diabetes 
management program.
Compared with passive program participation, active par-
ticipation is associated with larger reduction in inpatient 
days  and  ED  visits  and  higher  rates  of  recommended 
screening.  Active  participants  also  experienced  larger 
increases  in  ambulatory  visits  and  smaller  decreases 
in  use  of  medications.  These  differences  in  outcomes 
by  participation  intensity  were  not  as  pronounced  as 
expected. The voluntary nature of this program, in which 
patients could choose their participation intensity, war-
rants caution when making comparisons between active 
and  passive  participants.  We  controlled  for  differences 
between active and passive participants, such as active 
participants’ slightly higher preprogram expenditures for 
diabetes-related health care services, by using prediction 
equations. In addition, we controlled for differences that 
likely correlated with patients’ motivation to improve their 
health: active participants had higher rates of receiving at 
least 1 HbA1c test, retinal examination, and microalbu-
min urine test annually.
This study had several limitations. Patients could opt out 
of the disease management program, whereas the HCG 
had no opt-out component. Anecdotal evidence suggests 
that many who opted out would have been excluded from 
the HCG, for example, patients who would soon be leaving 
the Military Health System. Observed characteristics for 
the opt-out group were similar to those of program partici-
pants. The opt-out nature of this program also meant that 
there was no similar concurrent control group.
The HCG was part of our study design because comparing 
program  outcomes  for  TRICARE’s  disease  management 
program with outcomes from published literature would 
have posed multiple problems. These include the dated-
ness of published findings and the differences in popula-
tions, diseases, program designs, and insurance benefits. 
Identifying an HCG that met the eligibility criteria for pro-
gram participation within the TRICARE health plan lim-
ited these issues. By using prediction equations, we could 
control for differences between the HCG and program par-
ticipants (17). A limitation of this approach is that secular 
trends continue to change health care delivery patterns. 
To mitigate the potential bias from secular trends we 1) 
chose an HCG that predated the disease manage program 
only slightly, 2) used patient preprogram characteristics to 
predict outcomes after program start, and 3) adjusted past 
health care costs to 2008 dollars.
Unobservable differences between active and passive par-
ticipants may explain the smaller-than-expected differenc-
es in outcomes. Our study, for example, does not control 
for the possibility that patients received adequate diabetes 
counseling from other sources (eg, primary care provider 
or  endocrinologist).  Such  information  is  unavailable  for 
both the HCG and the program participants. If patients 
who already receive good diabetes counseling from other 
sources  are  more  likely  to  be  passive  participants  then 
our prediction equations could overestimate the program’s 
effect on passive participants and underestimate the effect 
on active participants when comparing observed with pre-
dicted outcomes.
Another  limitation  is  the  inability  to  precisely  identify 
patients whose diabetes is controlled. The unavailability 
of  laboratory  results  (eg,  HbA1c  results)  prohibited  us 
from testing whether patients with extremely high glu-
cose levels benefited from the program more than patients 
with moderately high glucose levels. Some patients with 
no diagnosis code for uncontrolled diabetes undoubtedly 
had uncontrolled diabetes, and some patients with a prior 
diagnosis of uncontrolled diabetes likely had their diabetes 
under control at the start of disease management. This 
inexactness in identifying patients with uncontrolled dia-
betes may reduce the estimates of program differences by 
uncontrolled status.
TRICARE’s  education-based  disease  management  pro-
gram was associated with modest reductions in annual 
medical  costs  and  more  appropriate  use  of  health  care 
services.  Patients  with  prior  indications  of  uncontrolled 
diabetes actively participated in the program at the same 
rate as patients with no indication of uncontrolled diabe-
tes, and they appeared to benefit more from the program, 
leading to higher cost savings. This finding suggests that 
patients  with  indications  of  uncontrolled  diabetes  are 
strong  candidates  for  participation  in  diabetes  manage-
ment programs.
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Tables
Table 1. Characteristics and Outcomes of Participants in the TRICARE Diabetes Disease Management Program, United States, 2007-
2008
Characteristic/Outcome
Diabetes Status/Program Participation Statusa
All, n = 29,604
Historical Control 
Group,b n = 
23,778
Controlled Uncontrolled
Active, n = 4,204
Passive, n = 
12,624 Active, n = 3,332
Passive, n = 
9,444
Age, mean (SD), y .1 (8.0)c 3.0 (9.7) 3.9 (9.1)d 0.6 (11.) 2.6 (10.1) 3.0 (9.9)
Men, % 0c 8 37d   
Region, %
North 37c 22 31d 20 2 31
South 7c 2 1 2 1 1
West 16c 26 18d 28 2 28
Military branch, %
Army 1 39 38 39 39 39
Air Force 27 28 29 29 28 2
Navy 2 2 2 2 2 29
All other 7 7 8 7 7 7
Managed care plan, % 62c 7 72d 67 63 63
Preventive care received in previous 12 months, %
HbA1c test c 3 71d 66  28
Retinal exam 23c 19 3d 30 2 23
Microalbumin urine test 32c 28 7 7 37 16
Charlson comorbidity 
score,e mean (SD)
0.9 (1.2)c 0.8 (1.2) 1.3 (1.)d 1.1 (1.) 0.9 (1.3) 0.7 (1.2)
Health care use, mean (SD)
No. of ED visits 1.6 (2.) 1.6 (3.1) 2.1 (3.8) 2.1 (3.7) 1.8 (3.3) 1.8 (3.)
No. of inpatient days 1. (.0) 1. (.8) 3.2 (9.2) 3.0 (8.9) 2.1 (7.3) 2. (8.1)
No. of ambulatory visits 22 (2)c 18 (22) 33 (29)d 27 (26) 23 (2) 22 (23)
No. of 30-day prescriptions 93 (7)c 77 () 10 (60)d 86 (6) 8 (6) 81 ()
Diabetes-related costs,f 
mean (SD), $
,18 (,02)c 3,607 (,160) 7,398 (8,16)d 6,92 (8,82) ,169 (6,972) ,21 (7,738)
Total costs,f mean (SD), $  13,2 (19,663)c 11,10 (16,7) 20,387 (2,16)d 16,689 (21,770) 1,26 (20,181) 1,376 (21,907)
 
Abbreviations: SD, standard deviation; HbA1c, hemogloblin A1c; ED, emergency department. 
a Controlled defined as not having an episode of care with the International Classification of Diseases, Ninth Revision, diagnosis code for uncontrolled diabetes 
(20.02, 20.03) during the year preceding program eligibility. Uncontrolled defined as having at least 1 such episode. Active defined as receiving personal-
ized telephone counseling; passive defined as declining personalized counseling but receiving educational mailings. 
b Refers to patients who in October 200 met the criteria used later to determine eligibility for the diabetes disease management program established in June 
2007. 
c Significantly different from participants in the controlled, passive category at P < .0. Calculated by using a 2-tailed t test. 
d Significantly different from participants in the uncontrolled, passive category at P < .0. Calculated by using a 2-tailed t test. 
e An index of comorbid conditions; a higher score indicates a sicker patient (12). 
f Adjusted to the medical component of the Consumer Price Index in 2008 (10).VOLUME 8: NO. 3
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Table 2. Health Care Costs, by Diabetes Status, Before and After Participation in the TRICARE Diabetes Disease Management 
Program, United States, 2007-2008a
Cost Category/
Diabetes Statusb Period
Historical Control Group (HCG),c n 
= 23,778 Program Participants, n = 29,604
Difference Between HCG and 
Participants
Mean Per-
Person Annual 
Cost,d $
Pre-Post 
Change, %
Mean Per-
Person Annual 
Cost,d $
Pre-Post 
Change, % $ %
Diabetes costs
Controlled
Pre 3,720
−27.8
3,68
−34.6 −200 −6.8
Post 2,687 2,33
Uncontrolled
Pre 6,822
−27.4
6,627
−34.7 −427 −7.3
Post ,90 ,328
All
Pre ,21
−27.6
,169
−34.6 −353 −7.1
Post 3,777 3,378
Total costs
Controlled
Pre 11,239
−14.4
11,307
−19.3 −564 −4.9
Post 9,620 9,12
Uncontrolled
Pre 17,71
−19.4
16,97
−21.0 −120 −1.6
Post 1,308 13,39
All
Pre 1,376
−17.4
1,26
−20.4 −408 −3.0
Post 11,879 11,39
 
a Unadjusted for case mix. 
b Controlled defined as not having an episode of care with the International Classification of Diseases, Ninth Revision, diagnosis code for uncontrolled diabetes 
(20.02, 20.03) during the year preceding program eligibility. Uncontrolled defined as having at least 1 such episode. 
c Refers to patients who in October 200 met the criteria used later to determine eligibility for the diabetes disease management program established in June 
2007. 
d Adjusted to the medical component of the Consumer Price Index in 2008 (10).VOLUME 8: NO. 3
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Table 3. Predicted and Observed Diabetes-Related Health Care Use and Costs for Participants in the TRICARE Diabetes Disease 
Management Program, United States, 2007-2008a
Outcome
Diabetes Status/Program Participation Statusb
All, n = 29,604
Controlled, n = 
16,828
Uncontrolled, n = 
12,776 Active, n = 7,536
Passive, n = 
22,068
Observed outcome
Total costs,c mean (SD), $ 2,16 (3,633) ,1 (6,68) 3,692 (,626) 3,271 (,67) 3,378 (,269)
No. of inpatient days, mean (SD) 0.1 (1.2) 0. (2.8) 0.2 (1.) 0.3 (2.2) 0.3 (2)
No. of ED visits, mean (SD) 0.2 (0.6) 0.3 (1.1) 0.2 (0.8) 0.2 (0.8) 0.2 (0.8)
No. of ambulatory visits, mean (SD) 3.8 (.6) 6.6 (6.7) .7 (6.1) .7 (.6) .0 (.8)
No. of 30-day prescriptions, mean (SD) 19 (1) 23 (1) 23 (1) 20 (1) 21 (1)
Received HbA1c test, % 3 71 69 8 61
Received retinal exam, % 22 31 32 2 26
Received microalbumin urine test, % 33 7  37 39
Predicted outcome
Total costs,c mean (SD), $ 2,67 (1,676) ,90 (3,032) 3,900 (2,8) 3,3 (2,622) 3,627 (2,608)
No. of inpatient days, mean (SD) 0.2 (0.2) 0. (1.2) 0.3 (0.7) 0.3 (0.9) 0.3 (0.8)
No. of ED visits, mean (SD) 0.1 (0.1) 0.3 (0.) 0.2 (0.3) 0.2 (0.3) 0.2 (0.3)
No. of ambulatory visits, mean (SD) 3.6 (2.1) 6. (2.8) .3 (2.9) .7 (2.7) .9 (2.8)
No. of 30-day prescriptions, mean (SD) 21 (12) 2 (11) 2 (12) 21 (12) 22 (12)
Received HbA1c test, % 0 69 63 7 8
Received retinal exam, % 20 27 26 23 23
Received microalbumin urine test, % 28 1 3 33 33
Difference in observed and predicted outcomesd
Total costs,c $ −141 −391 −208 −263 −249
No. of inpatient days −0.03 −0.07 −0.09 −0.03 −0.05
No. of ED visits 0.01 0.03 0.002 0.03 0.02
No. of ambulatory visits 0.1 0.11 0.2 0.02 0.13
No. of 30-day prescriptions  −1.3 −0.9 −0.4 −1.3 −1.1
Received HbA1c test, % 3 2 6 1 2
Received retinal exam, % 2 3 7 1 2
Received microalbumin urine test, % 6 7 9  6
 
Abbreviations: SD, standard deviation; ED, emergency department; HbA1c, hemoglobin A1c. 
a Adjusted for case mix. 
b Controlled defined as not having an episode of care with the International Classification of Diseases, Ninth Revision, diagnosis code for uncontrolled diabetes 
(20.02, 20.03) during the year preceding program eligibility. Uncontrolled defined as having at least 1 such episode. Active defined as receiving personal-
ized telephone counseling; passive defined as declining personalized counseling but receiving educational mailings. 
c Adjusted to the medical component of the Consumer Price Index in 2008 (10). 
d All differences between observed and predicted outcomes were significant at P < .0, calculated by using a paired t test. Differences may not be exact 
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Table 4. Predicted and Observed Total Health Care Use and Costs for Participants in the TRICARE Diabetes Disease Management 
Program, United States, 2007-2008a
Outcome
Diabetes Status/Program Participation Statusb
All, n = 29,604
Controlled, n = 
16,828
Uncontrolled, n = 
12,776 Active, n = 7,536
Passive, n = 
22,068
Observed outcome
Total costs,c mean (SD), $ 9,619 (17,322) 13,60 (22,073) 12,922 (19,11) 10,82 (19,77) 11,39 (19,616)
No. of inpatient days, mean (SD) 1.1 (6.3) 1.9 (8.6) 1. (7.1) 1. (7.) 1. (7.)
No. of ED visits, mean (SD) 1.0 (2.8) 1.3 (3.9) 1.1 (3.) 1.1 (3.3) 1.1 (3.3)
No. of ambulatory visits, mean (SD) 17 (21) 2 (26) 23 (2) 19 (23) 20 (23)
No. of 30-day prescriptions, mean (SD) 78 (3) 87 () 9 (6) 77 (3) 82 ()
Predicted outcome
Total costs,c mean (SD), $ 10,2 (7,206) 1,627 (9,776) 13,820 (9,12) 11,68 (8,) 12,12 (8,686)
No. of inpatient days, mean (SD) 1.1 (1.) 2.0 (2.8) 1.6 (2.2) 1. (2.1) 1. (2.2)
No. of ED visits, mean (SD) 0.9 (1) 1.3 (1.) 1.1 (1.2) 1.0 (1.2) 1.1 (1.2)
No. of ambulatory visits, mean (SD) 16 (11) 22 (12) 21 (13) 18 (11) 19 (12)
No. of 30-day prescriptions, mean (SD) 8 () 92 () 99 () 8 () 87 ()
Difference in observed and predicted outcomesd
Total costs,c $ −636e −977e −898e −743e −783e
No. of inpatient days  −0.03 −0.15e −0.2e −0.03 −0.1
No. of ED visits 0.1e 0.1 −0.04 0.1e 0.1e
No. of ambulatory visits 0.8e 1.2e 1.8e 0.7e 1e
No. of 30-day prescriptions −6e −5e −4e −6e −6e
 
Abbreviations: SD, standard deviation; ED, emergency department; HbA1c, hemoglobin A1c. 
a Adjusted for case mix. 
b Controlled defined as not having an episode of care with the International Classification of Diseases, Ninth Revision, diagnosis code for uncontrolled diabetes 
(20.02, 20.03) during the year preceding program eligibility. Uncontrolled defined as having at least 1 such episode. Active defined as receiving personal-
ized telephone counseling; passive defined as declining personalized counseling but receiving educational mailings. 
c Adjusted to the medical component of the Consumer Price Index in 2008 (10). 
d Differences between observed and predicted outcomes may not be exact because of rounding. 
e Difference between observed and predicted outcomes significant at P < .0, calculated by using a paired t test.